Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.

@article{Hironaka2013RandomizedOP,
  title={Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.},
  author={Shuichi Hironaka and Shinya Ueda and Hisateru Yasui and Tomohiro Nishina and Masahiro Tsuda and Takehiko Tsumura and Naotoshi Sugimoto and Hideki Shimodaira and Shinya Tokunaga and Toshikazu Moriwaki and Taito Esaki and Michitaka Nagase and Kazumasa Fujitani and Kensei Yamaguchi and Takashi Ura and Yasuo Hamamoto and Satoshi Morita and Isamu Okamoto and Narikazu Boku and Ichinosuke Hyodo},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2013},
  volume={31 35},
  pages={
          4438-44
        }
}
PURPOSE This phase III study compared treatment with weekly paclitaxel and biweekly irinotecan in patients with advanced gastric cancer refractory to treatment with fluoropyrimidine plus platinum. PATIENTS AND METHODS Patients were randomly assigned to receive either paclitaxel (80 mg/m(2) on days 1, 8, and 15, every 4 weeks) or irinotecan (150 mg/m(2) on days 1 and 15, every 4 weeks). Primary end point was overall survival (OS), and secondary end points were progression-free survival (PFS… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 135 CITATIONS, ESTIMATED Infinity% COVERAGE

135 Citations

0102030'14'15'16'17'18'19
Citations per Year
Semantic Scholar estimates that this publication has 135 citations based on the available data.

See our FAQ for additional information.

Similar Papers

Loading similar papers…